467 related articles for article (PubMed ID: 33909203)
21. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
22. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
Wu Y; Dong Z; Wang J; Fang Q
BMJ Open; 2022 Nov; 12(11):e065299. PubMed ID: 36379662
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
Conte P; Schneeweiss A; Loibl S; Mamounas EP; von Minckwitz G; Mano MS; Untch M; Huang CS; Wolmark N; Rastogi P; D'Hondt V; Redondo A; Stamatovic L; Bonnefoi H; Castro-Salguero H; Fischer HH; Wahl T; Song C; Boulet T; Trask P; Geyer CE
Cancer; 2020 Jul; 126(13):3132-3139. PubMed ID: 32286687
[TBL] [Abstract][Full Text] [Related]
24. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman RA; Gelman RS; Anders CK; Melisko ME; Parsons HA; Cropp AM; Silvestri K; Cotter CM; Componeschi KP; Marte JM; Connolly RM; Moy B; Van Poznak CH; Blackwell KL; Puhalla SL; Jankowitz RC; Smith KL; Ibrahim N; Moynihan TJ; O'Sullivan CC; Nangia J; Niravath P; Tung N; Pohlmann PR; Burns R; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU;
J Clin Oncol; 2019 May; 37(13):1081-1089. PubMed ID: 30860945
[TBL] [Abstract][Full Text] [Related]
25. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
Boyle FM; Smith IE; O'Shaughnessy J; Ejlertsen B; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Amonkar M; Huang Y; Rappold E; Williams LS; Wang-Silvanto J; Kaneko T; Finkelstein DM; Goss PE;
Eur J Cancer; 2015 Apr; 51(6):685-96. PubMed ID: 25752740
[TBL] [Abstract][Full Text] [Related]
26. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
Schmid P; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Mejia JA; Zhou X; Haiderali A; Nguyen AM; Cortes J; Winer EP
Eur J Cancer; 2023 Dec; 195():113393. PubMed ID: 37976633
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
Zhou X; Cella D; Cameron D; Amonkar MM; Segreti A; Stein S; Walker M; Geyer CE
Breast Cancer Res Treat; 2009 Oct; 117(3):577-89. PubMed ID: 19153829
[TBL] [Abstract][Full Text] [Related]
28. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Campone M; Beck JT; Gnant M; Neven P; Pritchard KI; Bachelot T; Provencher L; Rugo HS; Piccart M; Hortobagyi GN; Nunzi M; Heng DY; Baselga J; Komorowski A; Noguchi S; Horiguchi J; Bennett L; Ziemiecki R; Zhang J; Cahana A; Taran T; Sahmoud T; Burris HA
Curr Med Res Opin; 2013 Nov; 29(11):1463-73. PubMed ID: 23962028
[TBL] [Abstract][Full Text] [Related]
29. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
[TBL] [Abstract][Full Text] [Related]
30. Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
Jackisch C; Barcenas CH; Bartsch R; Palma JD; Glück S; Harbeck N; Macedo G; O'Shaughnessy J; Pistilli B; Ruiz-Borrego M; Rugo HS
Clin Breast Cancer; 2021 Oct; 21(5):e575-e583. PubMed ID: 33678567
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.
Yuan Y; Lee JS; Yost SE; Stiller T; Blanchard MS; Padam S; Katheria V; Kim H; Sun C; Tang A; Martinez N; Patel ND; Sedrak MS; Waisman J; Li D; Sanani S; Presant CA; Mortimer J
J Geriatr Oncol; 2021 Jun; 12(5):752-758. PubMed ID: 33663941
[TBL] [Abstract][Full Text] [Related]
32. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
[TBL] [Abstract][Full Text] [Related]
33. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.
Davie A; Carter GC; Rider A; Pike J; Lewis K; Bailey A; Price GL; Ringeisen F; Pivot X
BMC Cancer; 2020 Sep; 20(1):855. PubMed ID: 32894087
[TBL] [Abstract][Full Text] [Related]
34. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.
Dal Lago L; Uwimana AL; Coens C; Vuylsteke P; Curigliano G; Brouwers B; Jagiello-Gruszfeld A; Altintas S; Tryfonidis K; Poncet C; Bottomley A; Sousa B; Brain E; Wildiers H
J Geriatr Oncol; 2022 Jun; 13(5):582-593. PubMed ID: 35101364
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
[TBL] [Abstract][Full Text] [Related]
37. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
38. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE
García-Sáenz JA; Marmé F; Untch M; Bonnefoi H; Kim SB; Bear H; Mc Carthy N; Gelmon K; Martin M; Kelly CM; Reimer T; Toi M; Law E; Bhattacharyya H; Gnant M; Makris A; Seiler S; Burchardi N; Nekljudova V; Loibl S; Rugo HS
Eur J Cancer; 2024 Jan; 196():113420. PubMed ID: 38000218
[TBL] [Abstract][Full Text] [Related]
39. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
40. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials.
Rugo H; Brammer M; Zhang F; Lalla D
Clin Breast Cancer; 2010 Aug; 10(4):288-93. PubMed ID: 20705561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
